The 6-month in vitro antiviral evaluation and application study of "Qiyuan Brand" Jinlian Qingre Granules at the University of Shanghai for Science and Technology was completed in November 2020.

The research results show that Jinlian Qingre Granules have obvious in vitro inhibitory activity against the tested influenza virus strains and the new coronavirus SARS-CoV-2 Mpro protease. This laid a theoretical foundation for the later clinical promotion and anti-epidemic work of Jinlian Qingre Granules.